Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2558861 | 0.81 | KDM4E (0.56) | SMN1; SMN2KDM4EALDH1A1RAB9AHPGD | |
| SCHEMBL5252215 | 0.77 | HSD17B10 (0.48) | NPSR1SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL2146034 | 0.76 | NPSR1 (0.46) | NPSR1SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL10552507 | 0.76 | NPSR1 (0.46) | NPSR1SMN1; SMN2KDM4EALDH1A1RAB9A | |
| SCHEMBL1081091 | 0.76 | LMNA (0.54) | NPSR1SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL5433655 | 0.76 | NPSR1 (0.46) | NPSR1SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL24596263 | 0.74 | NPSR1 (0.45) | NPSR1SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL31087137 | 0.74 | NPSR1 (0.45) | NPSR1SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL1081092 | 0.73 | KDM4E (0.54) | NPSR1SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL16452385 | 0.72 | CYP2C19 (0.38) | NPSR1SMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119452084-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119317632-A | Oligonucleotide compositions and methods relating thereto | 波涛生命科学有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-111278827-B | Mutant isocitrate dehydrogenase inhibitors, compositions and methods thereof | 艾科生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| CN-111278827-A | Mutant isocitrate dehydrogenase inhibitors, compositions and methods thereof | 艾科生物科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
| EP-3658563-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | Isocure Biosciences Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660018-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-20200157111-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-05-21 | — | — | US | disclosed |
| US-20200140444-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200140444-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-05-07 | — | — | US | disclosed |
| WO-2019023165-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019023165-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20090023728-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1888529-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
| WO-2006124692-A2 | 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1699779-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061484-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | IKZF2, WEE1, NOTUM | NPSR1 3747/4885SMN1; SMN2 4699/4885KDM4E 2501/4885 |
| US-20090023728-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof | OPRD1, QDPR, RECQL | NPSR1 231/4885SMN1; SMN2 1102/4885KDM4E 1439/4885 |
| US-20200157111-A1 | PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE | IKZF2, WEE1, NOTUM | NPSR1 3747/4885SMN1; SMN2 4699/4885KDM4E 2501/4885 |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | NPSR1 3650/4885SMN1; SMN2 4362/4885KDM4E 1032/4885 |
| US-20200140444-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | NPSR1 4861/4885SMN1; SMN2 2494/4885KDM4E 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.